Market Overview:
The global palbociclib drug market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer, rising demand for targeted therapies, and growing investments in R&D. The global palbociclib drug market is segmented on the basis of type into tablets type and capsules type. On the basis of application, it is segmented into hospitals, diagnostic centers, and research institutes. Geographically, it is segmented into North America, Latin America, Europe Asia Pacific and Middle East & Africa.
Product Definition:
Palbociclib is a cancer medication that interferes with the growth and spread of cancer cells in the body. Palbociclib is used to treat breast cancer.
Tablets Type Palbociclib Drug:
Palbociclib (Ongentys) is an oral drug that is used in the treatment of breast cancer. It works by decreasing the activity of BRCA-1 and -2, which are responsible for causing the disease. The market for palbociclib was valued at USD 727 million in 2018 and it is expected to grow at a compound annual growth rate (CAGR) of 8% from 2019 to 2023.
Capsules Type Palbociclib Drug:
Capsules type palbociclib drug and it's usage in the Palbociclib Drug market is expected to witness significant growth over the forecast period. Capsules are small packages that hold drugs or medicine. They protect medicines from getting damaged and also help them to remain stable which makes them easy to consume for patients as well as doctors.
Application Insights:
The market is segmented by application into hospitals, diagnostic centers and research institutes. Hospitals were the largest revenue-generating centers in 2017 owing to a large patient base that requires chronic therapy for cancer. Palbociclib drugs are used as first line treatment for patients with hormone-receptor positive breast carcinoma who have undergone surgery and cannot be treated with hormones due to liver failure or intolerance.
Palbociclib drugs are also used in second line therapy after other therapies such as aromatase inhibitors fail or cannot be given due to resistance mutations caused by genetic abnormalities of the HRAS gene present on chromosome 17 which codes for the protein known as NRAS gene product (Non-Receptor Amino Acid Secreted). This drug is approved under U.S FDA approval program called Breakthrough Therapy Designation granted for advanced clinical trials which demonstrate substantial improvement over existing therapies while reducing toxicity compared to conventional chemotherapy medicines available in western countries.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, high adoption rate of technologically advanced drugs, and availability of approved tablets for palbociclib treatment. Moreover, increasing research funding by government & private entities is expected to boost product development in this region during the forecast period.
Asia Pacific is estimated to witness fastest growth over the forecast period owing to rising healthcare expenditure and awareness regarding early diagnosis among patients living with cancer. In addition, growing medical tourism industry will also contribute towards regional growth during the same period due to availability of affordable treatments in emerging countries such as India & China & South Korea etc.). Furthermore, increasing investments by major pharmaceutical companies for drug development will drive revenue generation further in this region thereby supporting a CAGR exceeding 6% from 2018 To 2030 in terms of value throughout the forecast year of 2017’s end-year (ending December 31).
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for the palbociclib drug market. According to a study by the World Health Organization (WHO), an estimated 14 million new cases of cancer were diagnosed in 2012, and this number is expected to rise to 24 million by 2035. This will create a large pool of patients who will require treatment with palbociclib and other anticancer drugs, driving the growth of the palbociclib drug market.
- Rising awareness about early detection and treatment: There is an increasing awareness among people about early detection and treatment of cancer, which is helping to drive demand for palbociclib and other anticancer drugs. In addition, governments are investing in initiatives aimed at raising awareness about cancer prevention and early diagnosis, which is also contributing to the growth of the palbociclib drug market.
- Growing use of targeted therapies: The growing use of targeted therapies such as palbociclib for treating various types of cancers is another key factor driving demand for this drug worldwide. Palbociclib has been shown to be effective against certain types tumors that are resistant to traditional chemotherapy regimens, making it an important tool in oncologists’ arsenal against cancer patients’ tumors cells mutations .This growing use will help fuel demand for Palbocelicib in coming years .
Scope Of The Report
Report Attributes
Report Details
Report Title
Palbociclib Drug Market Research Report
By Type
Tablets Type Palbociclib Drug, Capsules Type Palbociclib Drug
By Application
Hospitals, Diagnostic Centers, Research Institutes
By Companies
Pfizer, Beacon Pharmaceuticals, Incepta Pharmaceuticals, Bluepharma, NANO DARU
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
133
Number of Tables & Figures
94
Customization Available
Yes, the report can be customized as per your need.
Global Palbociclib Drug Market Report Segments:
The global Palbociclib Drug market is segmented on the basis of:
Types
Tablets Type Palbociclib Drug, Capsules Type Palbociclib Drug
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Diagnostic Centers, Research Institutes
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Beacon Pharmaceuticals
- Incepta Pharmaceuticals
- Bluepharma
- NANO DARU
Highlights of The Palbociclib Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Tablets Type Palbociclib Drug
- Capsules Type Palbociclib Drug
- By Application:
- Hospitals
- Diagnostic Centers
- Research Institutes
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Palbociclib Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Palbociclib is a drug that is used to treat cancer. It works by blocking the growth of cancer cells.
Some of the major players in the palbociclib drug market are Pfizer, Beacon Pharmaceuticals, Incepta Pharmaceuticals, Bluepharma, NANO DARU.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Palbociclib Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Palbociclib Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Palbociclib Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Palbociclib Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Palbociclib Drug Market Size & Forecast, 2018-2028
4.5.1 Palbociclib Drug Market Size and Y-o-Y Growth
4.5.2 Palbociclib Drug Market Absolute $ Opportunity
Chapter 5 Global Palbociclib Drug Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Palbociclib Drug Market Size Forecast by Type
5.2.1 Tablets Type Palbociclib Drug
5.2.2 Capsules Type Palbociclib Drug
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Palbociclib Drug Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Palbociclib Drug Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Diagnostic Centers
6.2.3 Research Institutes
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Palbociclib Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Palbociclib Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Palbociclib Drug Analysis and Forecast
9.1 Introduction
9.2 North America Palbociclib Drug Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Palbociclib Drug Market Size Forecast by Type
9.6.1 Tablets Type Palbociclib Drug
9.6.2 Capsules Type Palbociclib Drug
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Palbociclib Drug Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Diagnostic Centers
9.10.3 Research Institutes
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Palbociclib Drug Analysis and Forecast
10.1 Introduction
10.2 Europe Palbociclib Drug Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Palbociclib Drug Market Size Forecast by Type
10.6.1 Tablets Type Palbociclib Drug
10.6.2 Capsules Type Palbociclib Drug
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Palbociclib Drug Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Diagnostic Centers
10.10.3 Research Institutes
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Palbociclib Drug Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Palbociclib Drug Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Palbociclib Drug Market Size Forecast by Type
11.6.1 Tablets Type Palbociclib Drug
11.6.2 Capsules Type Palbociclib Drug
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Palbociclib Drug Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Diagnostic Centers
11.10.3 Research Institutes
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Palbociclib Drug Analysis and Forecast
12.1 Introduction
12.2 Latin America Palbociclib Drug Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Palbociclib Drug Market Size Forecast by Type
12.6.1 Tablets Type Palbociclib Drug
12.6.2 Capsules Type Palbociclib Drug
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Palbociclib Drug Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Diagnostic Centers
12.10.3 Research Institutes
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Palbociclib Drug Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Palbociclib Drug Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Palbociclib Drug Market Size Forecast by Type
13.6.1 Tablets Type Palbociclib Drug
13.6.2 Capsules Type Palbociclib Drug
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Palbociclib Drug Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Diagnostic Centers
13.10.3 Research Institutes
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Palbociclib Drug Market: Competitive Dashboard
14.2 Global Palbociclib Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Beacon Pharmaceuticals
14.3.3 Incepta Pharmaceuticals
14.3.4 Bluepharma
14.3.5 NANO DARU
